PharmaShots | Incisive News in 3 Shots

Subscribe Now

Clinical Trials

Gilead Reports Second Interim P-III (TROPiCS-02) Study Results of Trodelvy (sacituzumab govitecan-hziy) for HR+/HER2- Metastatic Breast Cancer

Gilead Reports Second Interim P-III (TROPiCS-02) Study Results of Trodelvy (sacituzumab govitecan-hziy) for HR+/HER2- Metastatic B...

August 16, 2022

Gamida Cell Reports First Patient Dosing in P-I/II Study of GDA-201 for the Treatment of Follicular and Diffuse Large B Cell Lymphoma

Gamida Cell Reports First Patient Dosing in P-I/II Study of GDA-201 for the Treatment of Follicular and Diffuse Large B Cell Lymph...

August 10, 2022

Innovent’s Picankibart (IBI112) Meet its Primary Endpoint in the P-II (CIBI112A201) Study for the Treatment of Plaque Psoriasis

Innovent’s Picankibart (IBI112) Meet its Primary Endpoint in the P-II (CIBI112A201) Study for the Treatment of Plaque Psoriasis

August 10, 2022

Innovent's Mazdutide (IBI362) Meet its Primary Endpoint in P-II Study for the Treatment of Type 2 Diabetes

Innovent's Mazdutide (IBI362) Meet its Primary Endpoint in P-II Study for the Treatment of Type 2 Diabetes

July 20, 2022

PureTech Founded Entity Akili Reports Investigator-Initiated Study Results of AKL-T01 for Systemic Lupus Erythematosus

PureTech Founded Entity Akili Reports Investigator-Initiated Study Results of AKL-T01 for Systemic Lupus Erythematosus

July 18, 2022

Regeneron & Sanofi Report P-III Trial Results of Dupixent (dupilumab) for Eosinophilic Esophagitis in Children Aged 1 to 11 Years

Regeneron & Sanofi Report P-III Trial Results of Dupixent (dupilumab) for Eosinophilic Esophagitis in Children Aged 1 to 11 Years

July 14, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us